unprocessed microscopy images Search Results


unprocessed human plasma uhpp  (Innovative Research Inc)
96
Innovative Research Inc unprocessed human plasma uhpp
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Unprocessed Human Plasma Uhpp, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/bio_rxiv__64898__2026__04__29__721601-44-1-8?v=Innovative+Research+Inc
Average 96 stars, based on 1 article reviews
unprocessed human plasma uhpp - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
data unprocessed gel images  (Vector Laboratories)
96
Vector Laboratories data unprocessed gel images
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Data Unprocessed Gel Images, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/pm35947956-279-301-295?v=Vector+Laboratories
Average 96 stars, based on 1 article reviews
data unprocessed gel images - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
haadf-stem image  (Verlag GmbH)
90
Verlag GmbH haadf-stem image
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Haadf Stem Image, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/10__1002_slash_adem__201800125-291-10-29?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
haadf-stem image - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
zeiss confocal images  (Carl Zeiss)
90
Carl Zeiss zeiss confocal images
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Zeiss Confocal Images, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/pm24375798-105-1-2?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
zeiss confocal images - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
fv1000 confocal laser scanning microscope  (Olympus)
99
Olympus fv1000 confocal laser scanning microscope
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Fv1000 Confocal Laser Scanning Microscope, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/pmc07550849-319-10-9?v=Olympus
Average 99 stars, based on 1 article reviews
fv1000 confocal laser scanning microscope - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
olympus szx10 stereo microscope  (Olympus)
96
Olympus olympus szx10 stereo microscope
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Olympus Szx10 Stereo Microscope, supplied by Olympus, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/bio_rxiv__2024__07__26__605346-216-8-8?v=Olympus
Average 96 stars, based on 1 article reviews
olympus szx10 stereo microscope - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
unprocessed microscopy images  (Mendeley Ltd)
86
Mendeley Ltd unprocessed microscopy images
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Unprocessed Microscopy Images, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/pmc12322038-461-0-6?v=Mendeley+Ltd
Average 86 stars, based on 1 article reviews
unprocessed microscopy images - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
axiophot microscope  (Carl Zeiss)
96
Carl Zeiss axiophot microscope
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Axiophot Microscope, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/pm11319856-133-15-14?v=Carl+Zeiss
Average 96 stars, based on 1 article reviews
axiophot microscope - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
digital micrograph software  (Gatan Inc)
97
Gatan Inc digital micrograph software
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Digital Micrograph Software, supplied by Gatan Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/unprocessed+microscopy+images/10__1007_slash_s10570___014___0308___1-52-10-13?v=Gatan+Inc
Average 97 stars, based on 1 article reviews
digital micrograph software - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier

Image Search Results


Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

Journal: bioRxiv

Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

doi: 10.64898/2026.04.29.721601

Figure Lengend Snippet: Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

Techniques: Isolation, BIA-KA, Western Blot, Concentration Assay, Acid Assay, Size-exclusion Chromatography, Transmission Assay, Electron Microscopy, Clinical Proteomics

Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

Journal: bioRxiv

Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

doi: 10.64898/2026.04.29.721601

Figure Lengend Snippet: Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

Techniques: Flow Cytometry, Isolation, Labeling, Imaging, Fluorescence, Size-exclusion Chromatography, Clinical Proteomics